Tipsheet
What matters at India’s listed companies
Pharmaceuticals · Micro cap

Astonea Labs raises ₹2.99 cr from Gurugram property sale

The nano-cap pharma seller unloaded two commercial units in JMD Megapolis IT Park to the Satija family. At just 1% of market cap, it's a modest cash boost.

2 earlier stories on Astonea Labs Ltd.
Mkt cap₹276 cr
P/E61.13×
ROE29.06%
Debt / eq.2.90
₹2.99 cr Proceeds from sale of two commercial units, ~1% of market cap

What's new

  • Sold two Gurugram commercial units for ₹1.50 cr each to Suresh and Santosh Satija.
  • Sale deed registered on 17 July 2026; total ₹2.99 cr received.
  • Proceeds equal roughly 1% of Astonea's ₹276 cr market cap.

Why this matters

For a nano-cap pharma company with ₹9.39 cr uninsured fire loss and a debt/equity of 2.90, even a small cash infusion helps. But ₹2.99 cr is less than one month's profit (₹3 cr in Mar quarter). It won't change the investment case.

What we're watching

  • Any plans for the cash (debt reduction, working capital, or capex).
  • Whether further property divestments follow.
  • Impact on quarterly cash flow statement.

The full read

Astonea Labs has sold two commercial units in Gurugram's JMD Megapolis IT Park to Suresh Kumar Satija and Santosh Satija for ₹2.99 crore, about 1% of its ₹276 crore market cap. The sale deed was registered on 17 July 2026. The cash is welcome for a nano-cap that recently reported an uninsured ₹9.39 crore fire loss and carries debt of 2.90 times equity. But ₹2.99 crore is less than one month's net profit (the Mar 2026 quarter delivered ₹3 crore). This transaction pads the balance sheet but doesn't alter the earnings picture. It is a small, clean asset monetization, nothing more.

Questions answered

How much did Astonea Labs get from the sale?
₹2.99 crore for two units at ₹1.50 crore each.
Who bought the units?
Suresh Kumar Satija and Santosh Satija.
Is this a big deal for the company?
No. The proceeds are roughly 1% of market cap and less than one quarter's net profit.
Why sell now?
Not specified; likely an opportunistic asset monetization.
What will Astonea do with the cash?
Not disclosed; may use for working capital or debt reduction given high leverage.
Mentioned: Suresh Kumar Satija · Santosh Satija · JMD Megapolis IT Park
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Astonea Labs Ltd.

Pharmaceuticals
₹292 cr
P/E 64.72×

Latest quarter · Mar 2026

Sales₹81 cr
Net profit₹3 cr
Op. margin+9.8%
EPS₹2.95

Strength & growth

Debt / equity2.90×
Current ratio1.12×
  1. 17 Jul 2026 · 6:14 PM IST Astonea Labs raises ₹2.99 cr from Gurugram property sale
  2. 14d ago Astonea Labs passes Yemeni drug regulator's facility inspection
  3. 38d ago Astonea Labs profit slides to ₹451.52 lakhs; ₹9.39 cr fire loss uninsured